734 related articles for article (PubMed ID: 20110006)
1. Changes in physicians' practice of prescribing cyclooxygenase-2 inhibitor after market withdrawal of rofecoxib: a retrospective study of physician-patient pairs in Taiwan.
Hsiao FY; Tsai YW; Huang WF
Clin Ther; 2009 Nov; 31(11):2618-27. PubMed ID: 20110006
[TBL] [Abstract][Full Text] [Related]
2. Retrospective analysis of utilization patterns and cost implications of coxibs among seniors in Quebec, Canada: what is the potential impact of the withdrawal of rofecoxib?
Rahme E; Hunsche E; Toubouti Y; Chabot I
Arthritis Rheum; 2006 Feb; 55(1):27-34. PubMed ID: 16463408
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the baseline cardiovascular risk profile among hypertensive patients prescribed COX-2-specific inhibitors or nonspecific NSAIDs: data from real-life practice.
Zhao SZ; Burke TA; Whelton A; von Allmen H; Henderson SC
Am J Manag Care; 2002 Oct; 8(15 Suppl):S392-400. PubMed ID: 12416789
[TBL] [Abstract][Full Text] [Related]
4. Channelling of COX-2 inhibitors to patients at higher gastrointestinal risk but not at lower cardiovascular risk: the Cox2 inhibitors and tNSAIDs description of users (CADEUS) study.
Depont F; Fourrier A; Merlière Y; Droz C; Amouretti M; Bégaud B; Bénichou J; Moride Y; Velo GP; Sturkenboom M; Blin P; Moore N;
Pharmacoepidemiol Drug Saf; 2007 Aug; 16(8):891-900. PubMed ID: 17351983
[TBL] [Abstract][Full Text] [Related]
5. Large-scale stopping and switching treatment with COX-2 inhibitors after the rofecoxib withdrawal.
Sukel MP; van der Linden MW; Chen C; Erkens JA; Herings RM
Pharmacoepidemiol Drug Saf; 2008 Jan; 17(1):9-19. PubMed ID: 17963198
[TBL] [Abstract][Full Text] [Related]
6. What happened to the prescribing of other COX-2 inhibitors, paracetamol and non-steroidal anti-inflammatory drugs when rofecoxib was withdrawn in Australia?
Barozzi N; Tett SE
Pharmacoepidemiol Drug Saf; 2007 Nov; 16(11):1184-91. PubMed ID: 17636557
[TBL] [Abstract][Full Text] [Related]
7. Withdrawal of COX-2 selective inhibitors rofecoxib and valdecoxib: impact on NSAID and gastroprotective drug prescribing and utilization.
Sun SX; Lee KY; Bertram CT; Goldstein JL
Curr Med Res Opin; 2007 Aug; 23(8):1859-66. PubMed ID: 17605893
[TBL] [Abstract][Full Text] [Related]
8. Association between nonnaproxen NSAIDs, COX-2 inhibitors and hospitalization for acute myocardial infarction among the elderly: a retrospective cohort study.
Rahme E; Watson DJ; Kong SX; Toubouti Y; LeLorier J
Pharmacoepidemiol Drug Saf; 2007 May; 16(5):493-503. PubMed ID: 17086567
[TBL] [Abstract][Full Text] [Related]
9. Cost of heart failure among hypertensive users of nonspecific NSAIDs and COX-2-specific inhibitors.
Zhao SZ; Burke TA; Whelton A; von Allmen H; Henderson SC
Am J Manag Care; 2002 Oct; 8(15 Suppl):S414-27. PubMed ID: 12416791
[TBL] [Abstract][Full Text] [Related]
10. Factors associated with celecoxib and rofecoxib utilization.
Rawson NS; Nourjah P; Grosser SC; Graham DJ
Ann Pharmacother; 2005 Apr; 39(4):597-602. PubMed ID: 15755796
[TBL] [Abstract][Full Text] [Related]
11. Thromboembolic cardiovascular risk among arthritis patients using cyclooxygenase-2-selective inhibitor or nonselective cyclooxygenase inhibitor nonsteroidal anti-inflammatory drugs.
Spalding WM; Reeves MJ; Whelton A
Am J Ther; 2007; 14(1):3-12. PubMed ID: 17303969
[TBL] [Abstract][Full Text] [Related]
12. COX-2-specific inhibitors: prescribing patterns in a large managed care health system and strategies to minimize costs.
Weideman RA; Kelly KC; Kelley CL; Cryer B
Am J Manag Care; 2002 Oct; 8(10):869-77. PubMed ID: 12395955
[TBL] [Abstract][Full Text] [Related]
13. Adoption of celecoxib and rofecoxib: a nationwide database study.
Helin-Salmivaara A; Huupponen R; Virtanen A; Klaukka T
J Clin Pharm Ther; 2005 Apr; 30(2):145-52. PubMed ID: 15811167
[TBL] [Abstract][Full Text] [Related]
14. Cardiovascular events associated with the use of four nonselective NSAIDs (etodolac, nabumetone, ibuprofen, or naproxen) versus a cyclooxygenase-2 inhibitor (celecoxib): a population-based analysis in Taiwanese adults.
Huang WF; Hsiao FY; Wen YW; Tsai YW
Clin Ther; 2006 Nov; 28(11):1827-36. PubMed ID: 17213003
[TBL] [Abstract][Full Text] [Related]
15. Prescription channeling of COX-2 inhibitors and traditional nonselective nonsteroidal anti-inflammatory drugs: a population-based case-control study.
Moride Y; Ducruet T; Boivin JF; Moore N; Perreault S; Zhao S
Arthritis Res Ther; 2005; 7(2):R333-42. PubMed ID: 15743481
[TBL] [Abstract][Full Text] [Related]
16. Concordance with guideline recommendations: previous and more recent nonsteroidal anti-inflammatory drug prescriptions in Quebec, Canada.
Rahme E; Roussy JP; Lafrance JP; Nedjar H; Morin S
Pharmacoepidemiol Drug Saf; 2012 Apr; 21(4):420-7. PubMed ID: 22223535
[TBL] [Abstract][Full Text] [Related]
17. A Medicare database review found that physician preferences increasingly outweighed patient characteristics as determinants of first-time prescriptions for COX-2 inhibitors.
Schneeweiss S; Glynn RJ; Avorn J; Solomon DH
J Clin Epidemiol; 2005 Jan; 58(1):98-102. PubMed ID: 15649677
[TBL] [Abstract][Full Text] [Related]
18. Blood pressure in Native Americans switched from celecoxib to rofecoxib.
Fredy J; Diggins DA; Morrill GB
Ann Pharmacother; 2005 May; 39(5):797-802. PubMed ID: 15797981
[TBL] [Abstract][Full Text] [Related]
19. Blood pressure destabilization and edema among 8538 users of celecoxib, rofecoxib, and nonselective nonsteroidal antiinflammatory drugs (NSAID) and nonusers of NSAID receiving ordinary clinical care.
Wolfe F; Zhao S; Pettitt D
J Rheumatol; 2004 Jun; 31(6):1143-51. PubMed ID: 15170928
[TBL] [Abstract][Full Text] [Related]
20. How direct-to-consumer television advertising for osteoarthritis drugs affects physicians' prescribing behavior.
Bradford WD; Kleit AN; Nietert PJ; Steyer T; McIlwain T; Ornstein S
Health Aff (Millwood); 2006; 25(5):1371-7. PubMed ID: 16966735
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
